This study identifies three evolutionary states of ovarian high-grade serous carcinoma using whole-genome sequencing and links them to distinct therapeutic targets.

bioRxiv · Aug 30, 2022Cancer Biology

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

W. Senkowski, L. Gall-Mas, M. M. Falco, Y. Li, K. Lavikka, M. C. Kriegbaum, J. Oikkonen, D. Bulanova, E. J. Pietras, K. Vossgröne, Y.-J. Chen, E. P. Erkan, M. K. Gronning Hog, I. M. Larsen, T. Lamminen, , K. Wennerberg

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

bioRxiv · Apr 21, 2022Cancer Biology

Single-cell RNA sequencing-based characterization of resident lung mesenchymal stromal cells in bronchopulmonary dysplasia

I. Mizikova, F. Lesage, C. Cyr-Depauw, D. P. Cook, M. Hurskainen, S. Hanninen, A. Vadivel, P. Bardin, S. Zhong, O. Carpen, B. C. Vanderhyden, B. Thebaud

This study uses scRNA-seq to characterize resident lung mesenchymal stromal cells in normal development and BPD, finding hyperoxia alters their gene expression and identifies Serpinf1 as a stable marker.

bioRxiv · Jun 18, 2021Cell Biology

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

A. N. Cvrljevic, U. Butt, K. Huhtinen, T. Gronroos, C. Bockelman, H. Lassus, K. Kaipio, A. Ristimaki, T. Arsiola, T. D. Laajala, D. Connolly, O. Carpen, J. Pouwels, J. Westermarck

The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.

bioRxiv · Mar 31, 2021Cancer Biology